List view / Grid view
Small molecules are essential for developing effective medicines, but their structural complexity and material behaviour present difficulties. In this article, Chris Brown, Senior Chemist, Onyx Scientific Ltd, discusses how the right technologies and approaches can enhance drug development and mitigate risk from initial phase to commercial launch.
Researchers screened over 2,000 small molecules and have now more than doubled the known compounds reported to induce trained immunity.
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
A new strategy enables researchers to be more precise in the control of gene expression of a therapeutic protein.
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
Novel findings about the tafazzin gene offers a potential new target and drug candidate for Barth syndrome.
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
Researchers from the University of Freiburg and the University of Cambridge have observed live cell formation of membraneless molecular aggregates, uncovering the interplay between biological mechanisms and physical force.
20 July 2023 | By Eurofins DiscoverX
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.
In this interview, Sam Hasson, Senior Director at Rgenta Therapeutics, shares his journey in drug discovery, from graduate school to industry, and his current work developing small molecule therapeutics to target RNA processing. He discusses the challenges and opportunities in the field of RNA-centric drug discovery and highlights the potential…
USC researcher Dr Steven Gazal and his team have identified human genome base pairs that have remained constant over millions of years of mammalian evolution. These base pairs are linked to human disease. Using DNA from 240 mammal species, they identified genetic variations affecting an individual's survival and reproduction.
